Maxim Group Issues Positive Forecast for Alterity Therapeutics (NASDAQ:ATHE) Stock Price

Alterity Therapeutics (NASDAQ:ATHE) had its target price lifted by stock analysts at Maxim Group from $8.00 to $12.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 162.58% from the company’s current price.

Alterity Therapeutics Stock Performance

Shares of Alterity Therapeutics stock traded up $1.66 during midday trading on Thursday, hitting $4.57. The company had a trading volume of 22,981,076 shares, compared to its average volume of 1,413,356. Alterity Therapeutics has a 52-week low of $1.00 and a 52-week high of $5.87. The company has a 50 day moving average of $2.64 and a 200 day moving average of $1.80.

Institutional Trading of Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC increased its holdings in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the quarter. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 2.14% of the stock is owned by institutional investors.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.